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Abstract
Background: Visceral leishmaniasis (VL) caused by an intracellular protozoan parasite Leishmania, is fatal in the absence of
treatment. At present there are no effective vaccines against any form of leishmaniasis. Here, we evaluate the potency,
efficacy and durability of DNA/DNA, DNA-prime/Protein-boost, and Protein/Protein based vaccination against VL in a
susceptible murine model.
Methods and Findings: To compare the potency, efficacy, and durability of DNA, protein and heterologous prime-boost
(HPB) vaccination against Leishmania donovani, major surface glycoprotein gp63 was cloned into mammalian expression
vector pcDNA3.1 for DNA based vaccines. We demonstrated that gp63 DNA based vaccination induced immune responses
and conferred protection against challenge infection. However, vaccination with HPB approach showed comparatively
enhanced cellular and humoral responses than other regimens and elicited early mixed Th1/Th2 responses before infection.
Moreover, challenge with parasites induced polarized Th1 responses with enhanced IFN-c, IL-12, nitric oxide, IgG2a/IgG1
ratio and reduced IL-4 and IL-10 responses compared to other vaccination strategies. Although, vaccination with gp63 DNA
either alone or mixed with CpG- ODN or heterologously prime-boosting with CpG- ODN showed comparable levels of
protection at short-term protection study, DNA-prime/Protein-boost in presence of CpG significantly reduced hepatic and
splenic parasite load by 107 fold and 1010 fold respectively, in long-term study. The extent of protection, obtained in this
study has till now not been achieved in long-term protection through HPB approach in susceptible BALB/c model against
VL. Interestingly, the HPB regimen also showed marked reduction in the footpad swelling of BALB/c mice against
Leishmania major infection.
Conclusion/Significance: HPB approach based on gp63 in association with CpG, resulted in robust cellular and humoral
responses correlating with durable protection against L. donovani challenge till twelve weeks post-vaccination. These results
emphasize the potential of DNA-prime/Protein-boost vaccination over DNA/DNA and Protein/Protein based vaccination in
maintaining long-term immunity against intracellular pathogen like Leishmania.
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Introduction
Leishmaniasis comprise of several diseases caused by a
unicellular, digenetic and most genetically diverse protozoan
parasites belonging to the genus Leishmania. The clinical manifes-
tations range from the self-limiting cutaneous infections to
overwhelming visceral disease. There are approximately 1.5
million cases of cutaneous leishmaniasis (CL) and 500,000 visceral
leishmaniasis (VL) cases per year [1,2]. Furthermore, the clinical
manifestations of human leishmaniasis depend on the infective
parasite species as well as on the host immune response. Current
control measures rely on chemotherapy, vector control and
control of reservoir host populations. The chemotherapeutic
agents used presently are expensive, toxic and emerging drug
resistance [3]. For these reasons, reinforced measures for
leishmaniasis control, particularly by the development of an
affordable and effective vaccine is highly recommended.
Genetic immunization is a relatively new tool for achieving
specific immune activation with several advantages such as
expression of concerned genes nearest to its native form, induction
of cellular immune response, persistent expression of desired
antigen (Ag) and induction of memory responses against the
infectious disease [4]. Moreover, host cells take up coding
plasmids, transcribe and translate the encoded gene, and produce
protein that stimulates an immune response when presented to the
immune system in the context of self-MHC [5–7]. Notably,
vaccination with plasmid DNA has been shown to induce
protective immunity through both MHC class I- and class II-
restricted T cell responses in a variety of infections [8–10].
Therefore, the plasmid DNA encoding specific Ag induced both
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CD4+ and CD8+ T cells, which is essential for protection against
intracellular diseases that require cell mediated immunity like
leishmaniasis [11]. Although DNA vaccines have proved effective
in the murine system, they are far less protective despite the high
doses used in humans [12–14]. On the other hand, protein based
vaccination induces CD4+ T cells probably through MHC-class II
restricted pathway resulting in enhanced humoral responses.
Despite these advantages, a major limitation in protein vaccination
is their inability to elicit strong, durable immune responses when
administered alone. Although substantial progress has been
obtained toward the effective vaccination strategy, most of the
responses they exhibited were short-lived. One promising
approach towards the development of potential vaccine candidate
in maintaining strong and durable immunity is the ‘‘prime-boost’’
strategy in which immune response is primed with a plasmid DNA
and subsequently boosted with either a protein Ag or with a
modified viral vector expressing the same Ag [15]. When mice
primed with DNA vaccine and later received the same Ag in the
form of recombinant protein as boost, production of Th1-type
cytokines was increased significantly, as was the IgG2 to IgG1
ratio [15]. In addition, heterologous prime-boost (HPB) vaccina-
tion strategy has gained significant momentum against wide ranges
of diseases include malaria [16], tuberculosis [17], influenza [18],
and HIV [19]. Previous attempts to enhance the protective
immune responses against experimental murine leishmaniasis were
successful using HPB vaccination strategy [20,21]. Several
leishmanial Ags have been examined as vaccine candidates against
murine VL model in prime-boost approach, such as, ORFF [22],
CPs [23], and LACK [24]. Moreover, comparative vaccine
potential of DNA, protein or HPB vaccination were evaluated
against cutaneous form of leishmaniasis in murine model [25].
While all of these studies have resulted in some degree of efficacy,
long-term protection (LTP) has rarely been observed. Therefore,
in an attempt to examine these findings, to compare the vaccine
efficacies and evaluate the durability of such vaccine regimens, we
selected gp63 in its DNA and a recombinant form as a vaccine
candidate against VL infection.
gp63, a highly conserved protein, is abundantly expressed in
promastigotes, and considered the major Ag determinant
recognized by the serum samples of patients obtained from
different clinical forms of leishmaniasis [26,27]. Moreover, gp63
has an intrinsic ability to stimulate protective immunity and is a
promising vaccine candidate against leishmaniasis. In our previous
study, we observed gp63 from Leishmania donovani when entrapped
within cationic liposomes elicited sustained immune responses
against experimental VL [28]. In the present study, we have
evaluated the protective and durable immunity raised through
gp63 by different vaccination strategies: DNA/DNA, DNA-
prime/Protein-boost, Protein/Protein in the susceptible BALB/c
mice against experimental VL using CpG-ODN as adjuvant. In
addition, we validated the efficiency of the gp63-based vaccine
against Leishmania major infection in BALB/c mice.
Materials and Methods
Animals and parasites
BALB/c mice 4–6 weeks old, reared in the animal care facility
under pathogen free conditions were used, for experimental
purposes. The studies were approved by the IICB Animal Ethical
Committee (147/1999/CPSCEA) and the animals were handled
according to their guidelines. L. donovani strain AG83 (MHOM/
IN/1983/AG83) was maintained by passage in Syrian Hamsters.
Promastigotes were cultured in Medium 199 supplemented with
penicillin G sodium (100 U/ml), streptomycin sulphate (100 mg/
ml) and 10% heat inactivated fetal bovine serum (FBS) (Sigma-
aldrich, St. Louis, MO). Parasites from stationary-phase culture
were sub-cultured to maintain an average density of 26106 cells/
ml [29]. L. major parasites (5ASKH) were grown in Medium 199
supplemented with penicillin G sodium (100 U/ml), streptomycin
sulphate (100 mg/ml) and 20% heat inactivated FBS at 22uC.
Plasmid construction
The gene encoding full-length gp63 of L. donovani (GenBank
accession number GQ301544) was subcloned from pET16b in
frame into pcDNA 3.1 (2/2) (Invitrogen, San Diego, CA) at the
BamHI/HindIII restriction sites. The full length gp63 was
amplified with gp63-specific primers. The primers used were 59
CGG GAT CCG GTA TGG GAT CCG TGG ACA GCA GCA
GCA CG (forward), and 59 CCC AAG CTT CTA GAG CGC
CAC GGC CAG CAG CGC (reverse) in a Thermocycler (Gene
Amp PCR System 9700; Applied Biosystems) using pfx Taq DNA
polymerase (Invitrogen). PCR conditions were one cycle of 5 min
at 94uC, 40 cycles of 1 min at 94uC, 1 min 20 s at 59.5uC, and
2 min at 72uC, followed by a final cycle of 7 min at 72uC.
Amplified PCR product was electrophoresed in agarose gel and
eluted from the gel (QIA quick gel extraction kit, Qiagen,
Valencia, CA). The eluted product was subsequently cloned into
mammalian expression vector pcDNA3.1 (2/2) and transformed
into competent Escherichia coli DH5a cells. The transformants were
screened for the presence of recombinant plasmids in presence of
ampicillin (Himedia, Mumbai, India). Isolated positive clones were
sequenced by DNA sequencer (ABI Prism, Model 377; Applied
Biosystems). Recombinant plasmids were then maintained and
propagated in DH5a E. coli. Endotoxin-free plasmid DNA was
isolated using Endo-free plasmid isolation kit (Qiagen) and used
for in vitro transfection and vaccination studies in BALB/c mice.
Transfection of plasmid constructs and Western blot
CHO-S cells (a gift from Dr. Shiv Sankar Roy) were maintained
in RPMI-1640 medium (Invitrogen) supplemented with 10% FBS.
The expression of gp63 was detected in mammalian cell by
transfecting pcDNA3.1-gp63 construct in CHO-S cell using
lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions with slight modifications. Briefly, CHO-S cells were
cultured at 16106 per well in 6-well plates to produce 85–90%
confluence on the day of transfection. Lipofectamine 2000 and
both pcDNA3.1 vector and pcDNA3.1-gp63 construct were
diluted in serum-free Opti-MEM media (invitrogen) at 17 ml/
250 ml and 8 mg/250 ml, respectively. The diluted lipofectamine
2000 and plasmid DNA were mixed together and incubated for
25 min at room temperature. The mixture was then added drop
wise onto the cell under gentle rocking condition, and incubated
for 45 min at room temperature. The transfected cells were
incubated 4–6 h at 37uC with 5% CO2. 1 ml of RPMI-1640
complemented with 10% FCS was added. The media was
replaced 24 h later with fresh media and transfected cells were
maintained in presence of 250 mg/ml of G418.
The lysate of stably transfected CHO-S cells was prepared and
subjected to SDS-PAGE. Thereafter, the protein bands were
electrophoretically transferred to PVDF membrane. To detect the
expressed protein, a primary polyclonal antibody against native
gp63 [28] was used at 1:1000 dilution followed by 1:1000 dilution
of HRP-conjugated goat anti-rabbit IgG secondary antibody
(Bangalore Genei, Bangalore, India).
Expression and purification of rgp63
The full-length gp63 was successfully cloned into pET16b vector
(Novagen, Madison, USA) previously. For expression of rgp63, E.
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coli BL21 (DE3) pLysS was transformed with pET16bLdgp63 and
the construct was grown in 1 L culture medium at 37uC until
OD600 nm 0.6 was reached. Protein production was then induced by
adding isopropyl b-D-thiogalactoside (IPTG) to a final concentra-
tion of 0.5 mM, and incubating for an additional 4 h at 23.5uC.
The culture was then harvested by centrifugation at 5,000 g, for
5 min, at 4uC, and the cell pellet was resuspended in 6 ml of
resuspension buffer (25 mM Tris-HCl, 500 mM NaCl, and 1 mg/
ml of Lysozyme, pH 8.0). The cell lysate was sonicated on ice for
5 min with 1 min pulse and 1 min interval between pulses using an
ultrasonicator (Misonix, Farmingdale, NY, USA). The sonicated
lysate was then centrifuged at 14,000 g for 25 min at 4uC and the
pellet containing inclusion bodies was solubilised with 5 ml of
solublization buffer (25 mM Tris-HCl, 500 mM NaCl, 8 M urea,
pH 8.0), kept at room temperature for 30 min and centrifuged at
12,000 g for 25 min. The supernatant containing solubilised protein
was loaded onto Ni2+-nitrilotriacetic acid-agarose (Ni-NTA) column
(Qiagen) and purified under denaturing condition. The agarose
column was pre equilibriated with equilibriation buffer (25 mM
Tris-HCl, 500 mM NaCl, 10 mM imidazole, 8 M urea, pH 8.0).
The column was washed with wash buffer (25 mM Tris-HCl,
500 mM NaCl, 50 mM imidazole, 8 M urea, pH 8.0) and eluted
with elution buffer (25 mM Tris-HCl, 500 mM NaCl, 500 mM
imidazole, 8 M urea, pH 8.0). To refold, the purified materials were
diluted 2 fold in dilution buffer containing 25 mM Tris-HCl,
500 mM NaCl, 500 mM imidazole, pH 8.0, and then dialyzed
against 25 mM Tris-HCl, 250 mM NaCl, pH 8.0 with decreasing
concentration of urea and imidazole. The recombinant proteins
were concentrated by Amicon ultrafiltration using a 10-kDa cutoff
membrane, exchanged with 25 mM Tris-HCl, 200 mM NaCl,
pH 8.0, and finally stored at 270uC. Protein concentrations were
determined by Lowry method [30]. Purity and homogeneity of
purified proteins was checked by using SDS-PAGE, and the gel was
subsequently stained with silver nitrate.
Immunization of mice and challenge infection
For immunization, BALB/c mice were injected intramuscularly
(i.m.) in the hind leg thigh muscle with 50 mg (in 50 ml of PBS) of
pcDNA3.1 (2/2) (only vector) or pcDNA3.1-gp63 or PBS. In
some groups, CpG-ODN-1826 (20 mg) was used as an adjuvant in
combination with plasmid construct. The oligodeoxy nucleotide
was synthesized with a nuclease resistant phopshorothioate
backbone (Imperial Life Sciences, Haryana, India) and the
sequence was 59 TCC ATG ACG TTC CTG ACG TT 39. This
ODN contained two copies of a CpG motif known to have potent
immunostimulatory effects on the murine system [31].
There were two groups in which mice received DNA vaccine
either alone (36gp63 DNA) or in presence of CpG-ODN (36gp63
DNA+CpG). For immunization with protein, mice were injected
through subcutaneous (s.c.) route with 5 mg of rgp63 in combination
with 20 mg of CpG-ODN (36 rgp63+CpG). In the heterologous
group, mice were primed with two injections of pcDNA3.1-gp63
construct plus CpG, and boosted once with rgp63 plus CpG (26
gp63 DNA+CpG/rgp63+CpG). In some experiments, mice were
immunized with either CpG-ODN or rgp63 alone.
For all immunization study, all groups were boosted twice at 2-
week intervals. Ten days and twelve weeks after the final booster
mice were challenged with 2.56107 freshly transformed stationary
phase L. donovani promastigotes in 200 ml PBS injected intrave-
nously as described earlier [29]. For cutaneous infection, 26106
stationary phase L. major promastigotes were injected subcutane-
ously in the hind footpad. Weekly footpad swelling measurements
were recorded using caliper (Starrett Company, Athol, MA).
Measurement of delayed type hypersensitivity responses
(DTH)
DTH response was determined by measuring the difference in
the footpad swelling at 24 h following inoculation of the test
footpad with 25 ml of rgp63 (200 mg/ml) from that of the control
(PBS-injected) footpad with a constant pressure caliper [29].
Determination of antibody responses
Serum samples of individual mice were obtained before
infection, at ten days post vaccination for short-term and twelve
weeks post-vaccination for long-term, and after infection, 3
months post challenge for both short and long-term studies. Sera
of individual mice were assayed for the presence of gp63-specific
IgG1, IgG2a antibodies using enzyme-linked immunosorbent
assay (ELISA) as described earlier [29]. In brief, 96-well microtiter
plates (Nunc, Naperville, IL) were coated with rgp63 (5 mg/ml)
and blocked to prevent nonspecific binding. The plates were then
incubated with sera at a 1:200 dilution, followed by horseradish
peroxidase (HRP)-conjugated goat IgG1, and IgG2a (1:1,000) (BD
Pharmingen, San Diego, CA). The color reaction was developed,
and the absorbance was read in an ELISA plate reader (Thermo,
Waltham, MA) at 450 nm [29].
Cell proliferation and cytokine assays
Spleens were removed aseptically from experimental mice at the
indicated time before and after infection, and the single cell
suspensions were prepared in RPMI-1640 supplemented with
penicillin G sodium (100 U/ml), streptomycin sulphate (100 mg/
ml) and 10% heat inactivated FBS and 50 mM mercaptoethanol
(Sigma-Aldrich, St. Loius, MO). Erythrocytes were removed by
lysis with 0.14 M Tris-buffered NH4Cl. The splenocytes were
washed twice and resuspended in the culture medium, and viable
mononuclear cell numbers were determined by trypan blue
exclusion [32]. The cells were then cultured in triplicate in a 96
well flat bottom plate (Nunc, Roskilde, Denmark) at a density of
26105 cells/well in a final volume of 200 ml complete medium
and stimulated with rgp63 (5 mg/ml). Cells were incubated at
37uC in a humified chamber containing 5% CO2. For cytokine
analysis, cells were stimulated for 96 h, and supernatants were
collected and the concentrations of of IFN-c, IL-4, IL-12(p40) and
IL-10 (BD Pharmingen,) were quantitated by ELISA in accor-
dance with the manufacturer’s instructions [32].
For blocking experiments, aliquots of viable splenocyte cells
were incubated with anti-CD4 and anti-CD8 monoclonal
antibodies (mAbs) or the respective control IgGs for 1 h at 4uC
and washed twice in complete medium. The efficiency of blocking
was checked by flow cytometry. Almost 93% of CD4+ and 75% of
CD8+ T cells were blocked through this procedure. Total, and
CD4- or CD8-blocked splenocytes [33] were stimulated in vitro
with medium alone or with rgp63 (5 mg/ml) for 96 h.
For cell proliferation assay, the cells were incubated for 96 h
and pulsed with 1 mCi of [3H]-Thymidine (Amersham Bioscienc-
es, Buckinghamshire, UK) per well 18 h before they were
harvested on glass fiber paper. Thymidine uptake was measured
in a b-scintillation counter (Beckman Instruments, Fullerton, CA)
[34].
Measurement of NO production
Nitric oxide (NO) levels, quantified by the accumulation of
nitrite in the culture medium, were measured as described
previously [32]. Briefly, 100 ml of splenocyte culture supernatants
were mixed with an equal volume of Griess reagent (1%
sulfanilamide and 0.1% N-1-naphthylethylene diamine hydrochlo-
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ride in 50% H3PO4) and incubated at room temperature for
10 min. Absorbance was then measured at 540 nm.
Evaluation of parasite burden in liver and spleen
Following 3 months post-challenge infection in both short-and
long-term studies, parasite load was evaluated by limiting dilution
assay (LDA) with slight modifications [35]. Briefly, a weighted
piece of liver or spleen from an experimental mouse was
homogenized in complete Schneider’s Drosophila medium
(Invitrogen, Grand island, USA) containing 10% heat inactivated
FBS and diluted with the same medium to a final concentration of
1 mg/ml. Five-fold serial dilutions of homogenized tissue suspen-
sions were then plated in a 96-well tissue culture plates (Nunc,
Roskilde, Denmark) and were cultured for one month at 22uC.
Wells were examined for viable and motile promastigotes at 5 day-
interval, and the reciprocal of the highest dilution that was positive
for parasites was considered to be the concentration of parasites
per mg of tissue. The total organ burden was calculated using the
weight of the respective organs.
Statistical analysis
One-way ANOVA analysis (Multiple comparisons Tukey’s post
hoc test) was performed using the GraphPad InStat software. A
value of p,0.05 was considered to be significant.
Results
Construction of full-length gp63 gene in mammalian
pcDNA3.1 (2/2) expression vector, its expression into
CHO cell line, and expression and purification of rgp63 in
E. coli strain
Full length GP63 was successfully subcloned in right orientation
under the mammalian expression vector pcDNA3.1 (2/2). The
positive clones were selected by using PCR and restriction enzyme
digestion analysis (Figure 1A), and the PCR product was further
sent for sequence analysis. The recombinant plasmids were then
transfected into the CHO cell line and the expression at the
protein level was confirmed by western blot analysis using anti-
gp63 antibody raised in rabbits (Figure 1B). The results showed
that the recombinants were correctly constructed and could be
expressed in mammalian cell line.
The over expressed protein from E. coli BL21 (DE3) pLysS cells
harboring plasmid pET16bLdgp63 was purified through Ni+2-
NTA agarose column under denaturing conditions. The recom-
binant protein was refolded, dialyzed and finally concentrated
using Amicon ultrafiltration 10-kDa cut-off membrane. The yield
of purified protein was approximately 0.5 mg per liter of culture.
Analysis of the purified rgp63 showed that the protein was
essentially homogeneous (Figure 1C).
Humoral responses
Since the outcome of VL may be determined by the extent of
immune system activation, it was highly important to characterize
the changes in the immunoglobulin ratios after immunization. It is
well established that the cytokines such as IFN-c and IL-4 direct
immunoglobulin class switching of IgG2a and IgG1, respectively.
We therefore analyzed rgp63-specific production of these
antibodies before infection. Although very low levels of IgG2a
and IgG1 titers in all vaccinated group was observed, sera from
mice immunized with HPB regimen showed significantly en-
hanced IgG2a (p,0.001), a surrogate marker for Th1, (Table 1) in
comparison to gp63 DNA vaccinated groups in short-term study.
This humoral response was maintained till twelve weeks after
vaccination, and reached levels that were significantly higher than
groups of mice receiving rgp63 along with CpG (Table 2)
(p,0.001). Moreover, IgG1, a surrogate marker for Th2 cell
differentiation, was elevated particularly in HPB vaccine groups
and mice receiving rgp63 and CpG in both short-and long-term
studies (Table 1 and 2). Therefore, mice vaccinated either
heterologously or homologously using protein based vaccination
with CpG- ODN were able to elicit mixed Th1/Th2 responses
before infection.
Next, we investigated IgG2a and IgG1 titers in all the
vaccinated mice following challenge with L. donovani. After
Figure 1. Cloning and expression of L. donovani gp63 in mammalian expression vector and purification from E. coli. (A) Clone
confirmation of gp63 in pcDNA3.1 (2/2) vector. M, lDNA digested with HindIII marker; lane 1, PCR of cloned construct; lane 2, BamHI/HindIII
digested pcDNA3.1-gp63 construct. (B) Expression of gp63 in transfected CHO cell line. Lane 1, western blot of pcDNA3.1-gp63 transfected construct
in CHO cell line; lane 2, western blot of pcDNA3.1 transfected vector in CHO cell line. (C) Silver nitrate staining of 10% SDS-PAGE, M, molecular mass
marker; lane 1, Purified recombinant gp63.
doi:10.1371/journal.pone.0014644.g001
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challenge infection, although mice immunized with rgp63 plus
CpG-ODN showed enhanced IgG2a and IgG1 titers, mice
vaccinated with either gp63 DNA alone or in association with
CpG-ODN or DNA-prime/Protein-boost slightly induced the
levels of IgG2a and IgG1 (Table 1 and 2). In the LTP study, twelve
weeks after final vaccination and at 3 months post-infection, only
gp63 DNA immunization increased IgG2a titer by 2.3 fold and
incorporation of CpG motifs to the gp63 DNA vaccination
increased the titer by 2.56 fold (Table 2). Most surprisingly, almost
4.22 fold IgG2a titer was obtained in mice receiving rgp63 along
Table 1. Ag-specific IgG isotype responses in mice vaccinated with different vaccine regimens in short-term protected group (ten
days post boost) before and 3 months after L. donovani challenge infection.
Time points
Vaccination groups (Short-term
protection) Antibody titer (O.D at 450 nm)
Serum IgG2a Serum IgG1 Ratio of serum IgG2a/IgG1
Before infection PBS 0.08960.1 0.09660.01 0.92660.04
Only Vector 0.09560. 0 0.10160.01 0.94060.05
36gp63 DNA 0.18360.01 0.12360.01 1.53160.22
36gp63 DNA + CpG 0.20560. 17 0.14460.01 1.34060.14
26gp63 DNA + CpG/rgp63 + CpG 0.360. 01a 0.18060.02 1.76560.28
36 rgp63 + CpG 0.25260.02 0.16760.01 1.53860.27
Post-infection PBS 0.14760.02 0.13560.02 0.92260.29
Only Vector 0.12760.01 0.13760.02 0.98360.14
36gp63 DNA 0.20860.01 0.10760.01 2.04260.27
36gp63 DNA + CpG 0.26860.01 0.11860.01 2.36560.18
26gp63 DNA + CpG/rgp63 + CpG 0.34360.02 0.11160.0 3.17660.24c
36 rgp63 + CpG 0.57560.02b 0.25860.01b 2.24460.16
Ten days after final immunization and 3 months after challenge infection, blood serum samples were collected and assayed for IgG2a, IgG1, and IgG2a:IgG1 by ELISA.
The results are shown as the mean absorbance values 6 S.E. of five individual mice per group, representative of two independent experiments with similar results.
p values were calculated using one-way ANOVA and Tukey’s multiple comparison test.
aSignificantly higher than gp63 DNA either free or in presence of CpG (p,0.001).
bSignificantly higher than DNA-prime/Protein-boost (p,0.001).
cSignificantly higher than gp63 DNA (p,0.05).
doi:10.1371/journal.pone.0014644.t001
Table 2. Ag-specific IgG isotype responses in mice vaccinated with different vaccine regimens in long-term protected group
(twelve weeks post boost) before and after 3 months L. donovani challenge infection.
Time points
Vaccination groups (Long-term
protection) Antibody titer (O.D at 450 nm)
Serum IgG2a Serum IgG1 Ratio of serum IgG2a/IgG1
Before infection PBS 0.08460.01 0.09660.01 0.87760.06
OV 0.09760.0 0.10560.0 0.76060.17
36gp63 DNA 0.14760.01 0.12360.01 1.19360.07
36gp63 DNA + CpG 0.17760.01 0.13960.01 1.28260.01
26gp63 DNA + CpG/rgp63 + CpG 0.30960.018b 0.20260.01a 1.53460.08
36 rgp63 + CpG 0.22160.01 0.18660.0 1.18460.04
Post-infection PBS 0.11960.0 0.16560.01 0.65460.14
OV 0.12860.0 0.17560.0 0.73160.03
36gp63 DNA 0.30460.01 0.10360.01 3.06160.32
36gp63 DNA + CpG 0.45660.05 0.12860.02 3.71060.44
26gp63 DNA + CpG/rgp63 + CpG 0.54860.03 0.13360.02 4.56260.74
36 rgp63 + CpG 0.93560.04c 0.33360.05c 3.01160.34
Twelve weeks after final immunization and 3 months after challenge infection, blood serum samples were collected and assayed for IgG2a, IgG1, and IgG2a:IgG1 by
ELISA. The results are shown as the mean absorbance values 6 S.E. of five individual mice per group, representative of two independent experiments with similar
results. p values were calculated using one-way ANOVA and Tukey’s multiple comparison test.
aSignificantly higher than gp63 DNA either free or in presence of CpG (p,0.001).
bSignificantly higher than gp63 DNA either alone or in association with CpG, and rgp63 plus CpG (p,0.001).
cSignificantly higher than DNA-prime/Protein-boost (p,0.001).
doi:10.1371/journal.pone.0014644.t002
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with CpG. Although protein based vaccination induced substantial
IgG2a responses after challenge infection, the IgG2a/IgG1 ratio
before and after infection in mice vaccinated with rgp63 plus CpG
and DNA-prime/Protein boost were 1.1860.04 and 3.0160.34
and 1.53460.085 and 4.56260.74 respectively, in long-term
experiments (Table 2).
Delayed type hypersensitivity and splenocyte
proliferation
To verify the generation of cellular immune responses in DNA/
DNA, DNA/Protein and Protein/Protein based vaccination
against experimental VL, we used gp63 vaccine in its various
forms in association with a TLR9 agonist, CpG-ODN.
DTH, an index of cell mediated immunity in vivo, and an Ag-
specific in vitro T cell proliferation assay revealed the status of
cellular responses generated in vaccinated animals. We were
therefore interested to see the DTH and proliferative responses
elicited by vaccinated and challenged animals. BALB/c mice
immunized heterologously showed significantly higher DTH
responses compared to mice vaccinated with gp63 DNA alone
or rgp63 mixed with CpG (p,0.05) before infection in both short-
as well as long-term experiments (Figure 2A and B). Moreover,
Ag-specific proliferative responses elicited by HPB vaccination
regimen was significantly (p,0.001) higher in comparison to mice
vaccinated with only gp63 DNA and protein plus CpG vaccinated
group in both types of protection study (Figure 2C and D). The
specificity of the responses after gp63 vaccination was tested using
gp63-non related protein such as Cysteine Protease A (CPA) of L.
donovani. Inoculation of test footpad of BALB/c mice or in vitro
splenocytes pulsing with recombinant CPA (rCPA) confirmed that
the responses generated herein were specific to gp63 and not to
other gp63 non-related protein, rCPA (data not shown).
Challenge with L. donovani induced enhanced DTH responses
and rgp63-specific T cell proliferation in all vaccinated mice.
Among the different vaccinated groups, mice receiving heterolo-
gous immunization exhibited the highest degree of both DTH and
proliferative response of splenocytes compared to mice vaccinated
with gp63 DNA alone or rgp63 in association with CpG in short-
term protection (STP) study (Figure 2E and G).
In the long-term, the proliferative responses of splenocytes from
heterologously vaccinated mice increased from 96006578.8 cpm
to 115466610.8 cpm after challenge infection suggesting that
DNA-prime/Protein-boost regimen induced long-term cellular
responses compared to all vaccinated mice (p,0.001) (Figure 2D
and H). Therefore, vaccination with DNA-Prime/Protein-boost
showed highest Ag-specific DTH and proliferative responses in
comparison to either DNA/DNA or Protein/Protein vaccination
before and after L. donovani challenge infection.
Cytokine responses
It is well established that the cytokine milieu at the initiation of
infection is critical in determining disease outcome [36-37]. So to
understand the interplay between the disease healing inflamma-
tory cytokines IFN-c, and IL-12 and disease associated cytokines
IL-10 and IL-4, we sought to investigate Ag-specific in vitro
production of cytokines before and after challenge infection in
both STP and LTP studies.
Mice immunized with different forms of gp63 vaccines induced
IFN-c before infection (Figure 3A and B). Addition of CpG to
gp63DNA resulted in enhancement of IFN-c production from
(96.669.516) pg/ml to (155.8610.92) pg/ml in STP study
(Figure 3A). Therefore, addition of CpG to gp63 DNA skewed
the response towards Th1 type. Furthermore, HPB regimen
secreted significantly higher levels of IFN-c (27567.8 pg/ml) in
comparison to mice receiving rgp63 in association with CpG or
gp63 DNA either alone or in combination with CpG. These
responses were almost maintained after twelve weeks post-
vaccination (Figure 3B). The IFN-c responses in splenocytes
measured after L. donovani challenge also demonstrated that there
was a higher IFN-c for DNA-prime/Protein-boost vaccination
than in others (Figure 3C and D). Therefore, the in vitro
restimulation with rgp63 at twelve weeks after booster vaccination
demonstrated that there was induction of IFN-c responses in HPB
regimen more significantly compared to other vaccinated
strategies. We then analyzed, the contribution of CD4+ and
CD8+ T cells to the rgp63-specific production of IFN-c in vitro. As
shown in figure (3E and F) cytokine synthesis induced by rgp63 in
DNA based vaccine was mainly inhibited by mAb to CD8+ T cells
and partially inhibited by anti-CD4+ mAb. In contrast, production
of IFN-c mainly inhibited by anti-CD4+ Ab and partially by anti-
CD8+ Abs in mice vaccinated with rgp63 along with CpG.
However, in DNA-prime/Protein-boost based vaccination, con-
tribution of both these cell types was involved.
Similar pattern was observed also in IL-12 production
(Figure 4A-D). Highest IL-12 production was observed in mice
vaccinated with DNA-prime/Protein-boost group, which was
significantly higher in mice vaccinated with either gp63 alone
(p,0.001), or in combination with CpG (p,0.05), or rgp63 in
association with CpG (p,0.001) in both short and long-term
studies before challenge infection (Figure 4A and B). After
challenge infection, the level of IL-12 was enhanced further in
all vaccinated groups of mice in both STP and LTP experiments
(Figure 4C and D) and the level of IL-12 production in HPB
regimen was significantly higher than all the other vaccinated
groups. Moreover, HPB vaccination increased IL-12 levels by 1.34
fold and 1.58 fold in both short-and long-term protected group
after Leishmania challenge.
However, before and after infection, the levels of IL-4, an
established Th2 cytokine, was significantly higher in mice
vaccinated heterologously compared to mice receiving gp63
DNA alone (p,0.001), or in association with CpG (p,0.01) and
rgp63 plus CpG (p,0.001) (Figure 4E and F). Conversely, level of
expression of Th1 suppressive cytokine, IL-10 was unaffected in
vaccinated mice compared to controls (Figure 4I and J).
At 3 months post-infection, both STP and LTP studies revealed
that mice vaccinated with HPB vaccination could significantly
down regulate IL-4 in comparison to controls (p,0.01) (Figure 4G
and H). In case of challenge infection, HPB regimen showed
almost 2.35 fold and 2.28 fold reductions in IL-4 in STP and LTP
studies respectively compared to control PBS. Similarly, mice
prophylactically immunized with DNA-prime/Protein-boost re-
sulted in 2.56 fold and 3.5 fold decreased IL-10 secretion
compared to control after L. donovani infection in both short as
well as long-term studies respectively. Furthermore, down
regulation of IL-10 production from splenocytes of HPB regimen
was significantly lower than group of mice receiving rgp63 plus
CpG or gp63 DNA alone, in the long-term (p,0.05) (Figure 4L).
Hence the results demonstrate generation of early mixed Th1/
Th2 responses before infection, followed by strong Th1 biased
response in mice receiving DNA-prime/Protein-boost vaccine
after L. donovani challenge. Therefore, the vaccination strategies
employed with either DNA/DNA or Protein/Protein in presence
or absence of CpG have resulted weaker cellular responses than
DNA-prime/Protein-boost before and after challenge infection.
Measurement of NO
NO is the critical killing effector molecule against leishmaniasis
produced by IFN-c stimulated and inducible NO synthase-
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induced classical macrophages. To evaluate the killing effector
functions of prophylactic DNA/DNA, DNA-prime/Protein-boost,
Protein/Protein based approach in vaccinated and challenged
mice, NO was determined from splenocyte culture supernatant.
Spleen cells from PBS, only vector, gp63 DNA, gp63 DNA mixed
with CpG, HPB regimen, or rgp63 mixed with CpG-immunized
mice before and after infection in both short as well as long-term
protected groups were stimulated with rgp63 and supernatants
were tested for NO assay (Figure 5). We found that HPB regimen
showed considerably highest (18.5 and 17.4 mM) nitrite production
in short and long-term studies, before challenge infection. The
response was significantly higher than mice vaccinated with either
gp63 DNA alone (p,0.001), or gp63 DNA mixed with CpG
(p,0.05), and rgp63 associated with CpG (p,0.001) (Figure 5B) in
the long-term study. Moreover, after challenge infection, the HPB
regimen showed 22.6 and 25 mM nitrite production in both short
and long-term studies respectively. HPB regimen, therefore
showed highest magnitude of NO production which was
significantly higher than other vaccinated groups of mice
(p,0.001) (Figure 5C and D) and maintained till twelve weeks
post-vaccinated mice receiving L. donovani challenge infection.
Determination of splenic and liver parasite load following
challenge infection with L. donovani
Because HPB regimen showed impressive humoral and cellular
immune responses in comparison to other vaccinated groups, we
were interested to check the prophylactic efficacies of DNA/DNA,
DNA-prime/Protein-boost and Protein/Protein vaccines on the
clearance of splenic and hepatic parasite burden following
challenge infection. Fig. 6 illustrates the outcome of challenge
infection in BALB/c mice challenged either after ten days and
twelve weeks after last boosting and progression of infection was
monitored at 3 months. The degree of protection was quantified in
liver and spleen through serial dilution assay, which is more
reliable for monitoring low parasite loads as well as viable
parasites. Mice vaccinated with different vaccine formulations with
gp63 DNA showed comparable levels (almost 105–6 fold reductions
compared to PBS control, p,0.001) of protection against the
development of parasite burden in the liver of STP study
(Figure 6A). However, only 103 fold reduction (compared to
PBS, p,0.001) in hepatic parasite load was achieved in mice
vaccinated with rgp63 and CpG. Surprisingly, the parasite
clearance in the spleen was efficiently achieved by all the
vaccinated mice in STP study (Figure 6B). Mice vaccinated with
different gp63 DNA vaccine regimens showed comparable levels
(1011 fold reductions in parasite load compared to PBS, p,0.001)
of parasite clearance in spleen. However, almost 107-fold
reduction in parasite load was also obtained in mice vaccinated
with rgp63 mixed CpG, compared to control saline (p,0.001).
To evaluate the durability of the immunity induced by DNA/
DNA, DNA-prime/Protein-boost and Protein/Protein vaccines,
the length of protection was determined by examining the
responses to challenge infection at twelve weeks after booster
vaccination, sacrificed 3 months post-infection, and the parasite
load was again determined through serial dilution. Our data
demonstrate that, mice vaccinated heterologously showed signif-
icantly higher reduction in hepatic parasite load (almost 107 fold
compared to control PBS, p,0.001) in comparison to either only
gp63 DNA (p,0.001), or DNA mixed with CpG (p,0.01) and
rgp63 mixed with CpG (p,0.001) (Figure 6C). Similar responses
were observed in clearing parasites in spleen. HPB regimen
showed highest reduction in parasite load (almost 1010 fold
reduction compared to PBS, p,0.001) in comparison to gp63
DNA either alone or in association with CpG (p,0.001) or rgp63
mixed with CpG (p,0.001) (Figure 6D). Interestingly, mice
vaccinated heterologously, showed a hepatic parasite burden of
7.9 log1060.31 in short-term and 6.75 log1060.06 in long-term
and splenic parasite burden of 6.26 log1062.00 in short-term and
5.42 log1060.158 in LTP studies. Therefore, in terms of organ
parasite burdens, the immunity conferred by priming twice with
gp63 DNA mixed with CpG, followed by single boosting with
rgp63 mixed with CpG was more effective and its potency and
durability was maintained till twelve weeks.
Since HPB regimen showed durable immune responses against
L. donovani infection, we were interested to check the vaccine
efficacy of different gp63-based vaccination against CL. Mice
immunized with heterologously or rgp63 based vaccination
induced significantly smaller lesion size compared to PBS
(p,0.001, p,0.01) in STP (Figure 7A). Furthermore, in the LTP
study, all mice receiving gp63-based vaccination showed reduced
lesion size compared to PBS (p,0.001) (Figure 7B). Most
interestingly, vaccination with DNA-prime/Protein-boost showed
significantly lesser lesion sizes in comparison to the gp63 DNA
(p,0.05) or rgp63 plus CpG (p,0.01). Hence, the HPB approach
using L. donovani gp63 also validates its protective role against L.
major infection in BALB/c mice.
Discussion
In this study, we evaluate the comparative vaccine potential of
DNA/DNA, DNA-prime/Protein-boost, and Protein/Protein
based vaccination using gp63 with a toll-like receptor ligand
(TLR-9) agonist CpG-ODN in eliciting short- as well as long-
lasting immunity against infections with L. donovani in genetically
susceptible BALB/c mice. The results reported here suggest that
the control of infection was effectively achieved by DNA-prime/
Protein-boost based vaccination in a sustained manner. However,
the immunity conferred by DNA/DNA or Protein/Protein
vaccination was less effective particularly during long-lasting
study, while Protein/Protein-based vaccination induced partial
protection during short-term experiments. Since the goal of any
vaccine is to generate a sustain immune response over a long
period of time, we explored the effectivity of DNA-prime/Protein-
boost immunization with an immunomodulator, CpG-ODN over
DNA/DNA and Protein/Protein vaccination in LTP against VL
using gp63 as candidate vaccine.
Previous studies using gp63 DNA have been shown strong Th1
biased responses with varying levels of protection in mice against
Figure 2. DTH and splenocyte proliferation in mice vaccinated with gp63 with different vaccination approaches before and after 3
months challenge infection. Ten days, short-term protection (STP), and twelve weeks, long-term protection (LTP), after final boosting (post-
vaccination) (A–D), and 3 months after challenge infection (post-infection) (E–H) rgp63-specific DTH and splenocyte proliferation was measured. DTH
response was determined by measuring the difference in the footpad swelling at 24 h following inoculation of the test footpad with 25 ml of rgp63
(200 mg/ml) from that of the control (PBS-injected) footpad. Spleens were collected and splenocytes were re-stimulated in vitro for 96 h with 5 mg/ml
of rgp63 and pulsed with 1 mCi of [3H]-Thymidine for 18 h. Ag-specific splenocyte proliferation was determined by Thymidine incorporation and
expressed as counts per minute. Figures (A, B, E, F) represent DTH and (C, D, G, H) splenocyte proliferation in STP and LTP studies. The results are
shown as the mean values 6 S.E. of five individual mice per group, representative of two independent experiments with similar results. OV- only
vector. * p,0.05, ** p,0.01, *** p,0.001 as assessed by one-way ANOVA and Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0014644.g002
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the cutaneous form of the leishmaniasis [10,38–41]. Moreover,
with regard to L. donovani infection, genetic immunization with
gp63 either in DNA form or through HPB approach with rgp63
induced Th1 biased response, while protein boosting did not
significantly affect the efficacy of vaccines in terms of hepatic and
splenic parasite load [42]. Therefore, to evaluate the potency,
efficacy and durability, a comparative study using either genetic or
heterologous or protein-based vaccination with gp63 is required
against VL. Since successful vaccination in VL was associated with
an initial mixed Th1/Th2 response after immunization and with
challenge infection the response polarized towards Th1 with
further boosting of IFN-c and down regulation of IL-4 [32], we
Figure 3. IFN-c responses in BALB/c mice vaccinated with different vaccine approaches before and after 3 months challenge
infection. Levels of IFN-c ten days, short-term protection (STP), and twelve weeks, long-term protection (LTP) after final boosting (post-vaccination)
(A, B), and 3 months after challenge infection (post-infection) (C, D). Splenocytes were isolated from vaccinated mice, stimulated with rgp63 (5 mg/ml)
and were cultured for 96 h. The supernatants were collected, and assayed for IFN-c through ELISA. Figures (E, F) represent in vitro blocking
experiments either with anti-CD4+ or anti-CD8+ or both mAbs before (post-vaccination) and after L. donovani infection (post-infection). The results are
shown as the mean absorbance values 6 S.E. of five individual mice per group, representative of two independent experiments with similar results.
OV- only vector. * p,0.05, ** p,0.01, *** p,0.001 as assessed by one-way ANOVA and Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0014644.g003
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demonstrate, DNA-prime/Protein-boost vaccination strategy sig-
nificantly induced mixed Th1/Th2 responses after immunization,
while L. donovani challenge infection induced significantly strong
Th1 biased response compared to other vaccination strategies.
The difference we observed in our work with the published report
[42] could be due to the use of CpG-ODN in our formulations.
The results we obtained from our study is the first report, so far as
we are aware, of using different vaccination strategies with gp63
from L. donovani in short as well as long-lasting protection against
experimental VL.
A primary goal of vaccination is to induce memory responses
that will provide long-lived protection against severe disease by
Figure 4. IL-12, IL-4 and IL-10 responses in BALB/c mice vaccinated with different vaccine regimens before and after 3 months
challenge infection. Ten days, short-term protection (STP), and twelve weeks, long-term protection (LTP) after final boosting (post-vaccination),
and 3 months after challenge infection (post-infection) splenocytes were collected from vaccinated mice, stimulated with rgp63 (5 mg/ml) and were
cultured for 96 h. The supernatants were collected, and assayed for IL-12 (A–D), IL-4 (E–H), and IL-10 (I–L) through ELISA. The results are shown as the
mean absorbance values 6 S.E. of five individual mice per group, representative of two independent experiments with similar results. OV- only
vector. * p,0.05, ** p,0.01, *** p,0.001 as assessed by one-way ANOVA and Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0014644.g004
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intracellular pathogen. Despite maintaining sustained long-lasting
immunity through DNA vaccination against cutaneous form of
leishmaniasis [9,43], the reduction in parasite load was almost 103–4
folds depending on the types of tissue examined. Moreover, our
previous study with native gp63 demonstrated that liposomal
delivery of protein Ag conferred long-term protection was in
contrast to previous studies [33,43]. However, this result was
obtained through intraperitoneal (i.p.) immunization, a route that
was not desired for human vaccination [28]. Therefore, effective
vaccine strategies are still required for elicitation of immune
responses and durability against Leishmania infection.
Effective and successful vaccinations against intracellular patho-
gens require persuasive adjuvant that can induce strong immune
response. The adjuvant like properties of CpG-ODN on protein-
based vaccination was observed particularly in maintaining long-
lasting immunity [44] which overcome the need for IL-12 in
genetically susceptible BALB/c mice infected with L. major. In
addition, although, unmethylated CpG motifs within the plasmid
DNA vector have also been shown to contribute to the immunoge-
nicity of DNA vaccines [45,46], cloning additional CpG motifs or
adding CpG-ODN to the DNA vaccine rendered substantial immune
responses [47,48]. Therefore, using CpG-ODN was thought to be
effective regarding long-lasting protection against VL.
The nature of immune responses in vaccinated mice was
determined by the level of IgG2a and IgG1 antibody isotypes in
sera that associated with Th1 and Th2 response, respectively. We
observed mice immunized with HPB regimen showed early mixed
Th1/Th2 response that could lead to successful vaccination after
challenge. Induction of the anti-Leishmania IgG2a, and unaltered
IgG1 after infection in DNA vaccinated group, suggested
polarized Th1 responses. By contrast, conventional protein based
vaccine elicited enhanced Leishmania specific IgG2a and IgG1
antibody levels, particularly when combined with CpG ODN after
infection. Furthermore, L. donovani infection in HPB regimen
induced higher IgG2a/IgG1 ratio suggesting its strong ability
towards protective Th1 biased response.
Figure 5. Ag-specific NO levels in vaccinated mice before and after 3 months challenge infection. Ten days, short-term protection (STP),
and twelve weeks, long-term protection (LTP) after final boosting (post-vaccination), and 3 months after challenge infection (post-infection),
splenocytes from different vaccinated mice were isolated and stimulated with rgp63 (5 mg/ml) for 96 h and the level of NO was determined in
supernatants by Griess reagent. Figures (A, B) and (C, D) represent levels of NO before (post-vaccination) and after 3 months of L. donovani infection
(post-infection) respectively. The results are shown as the mean absorbance values 6 S.E. of five individual mice per group, representative of two
independent experiments with similar results. OV- only vector. * p,0.05, ** p,0.01, *** p,0.001 as assessed by one-way ANOVA and Tukey’s multiple
comparison test.
doi:10.1371/journal.pone.0014644.g005
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Because the cell mediated immune response is severely affected
during active VL due to T cell anergy specific to Leishmania Ags
[49,50], successful vaccination of humans and animals is often
related to Ag-induced DTH responses in vivo and T cell
proliferation in vitro [51]. We observed that vaccination heterol-
ogously resulted in an enhanced DTH and splenocyte proliferation
after infection, and the responses were efficiently maintained at
long-term. The ability to induce cell-mediated immunity by all
DNA vaccinated animals in presence or absence of CpG was
considerably higher than mice receiving protein Ag in association
with CpG. This enhanced cellular immune response obtained in
DNA/DNA or DNA-prime/Protein-boost vaccination only be-
cause of stability exhibited by DNA-based vaccines [52].
It is fairly well established that IFN-c and IL-12, the signature
cytokines of Th1 responses, are decreased during active VL.
Moreover, protective immunity against L. donovani, is dependent
on an IL-12 driven Th1 response and IFN-c production [53,54]
which results in the induction of parasite killing by macrophages
via the production of reactive nitrogen and oxygen intermediates
[55,56]. However, cured VL patients displayed both Th1 and Th2
type clones producing IFN-c, and IL-4 [57], control of L. donovani
in susceptible BALB/c mice was associated with mixed Th1/Th2
responses [58,59]. By contrast, there are reports of early mixed
Th1/Th2 responses before infection and polarized Th1 responses
after challenge infection leading protection against murine VL
[32,60]. Therefore, the existence of such a distinct Th1/Th2
polarization in VL is unclear. Hence, we analyze the cytokine
profile before and after challenge infection in all vaccinated mice.
IFN-c production was elevated in gp63 DNA plus CpG vaccinated
animals, while the responses was significantly enhanced after ten
days and twelve weeks post-immunization in HPB regimen, before
L. donovani challenge. Furthermore, co injection of CpG with either
gp63 DNA or with rgp63 has a clear adjuvant effect in inducing
IFN-c in comparison to only gp63 DNA and rgp63 (data not
Figure 6. Evaluation of protection against L. donovani challenge in mice vaccinated with different vaccine regimens. Quantification of
single viable cell was carried out by limiting dilution assay performed 3 months after infection on cells isolated from liver (A, C) and spleen (B, D) in
ten days, short-term protection (STP) (A, B) and twelve weeks, long-term protection (LTP) (C, D) studies. The cells were cultured in duplicate in
complete Schneider’s Drosophila medium containing 10% FCS for 1 month at 22uC in serial five-fold dilutions. The reciprocal of the highest dilution
that was positive for parasite growth was considered to be the concentration of parasites per mg of tissue. Results were expressed as log of total
organ parasite burden. Data represent the mean 6 S.E of five individual mice per group of one experiment. OV- only vector. ** p,0.01, *** p,0.001
as assessed by one-way ANOVA and Tukey’s multiple comparison test. *** p,0.001 in comparison to controls unless stated.
doi:10.1371/journal.pone.0014644.g006
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shown). However, almost comparable level of IFN-c was observed
in mice receiving gp63 DNA alone and rgp63 plus CpG-ODN.
Although, challenge with viable parasites enhanced IFN-c
production in all vaccinated mice except DNA-prime/Protein-
boost regimen, the significant level of IFN-c was still maintained in
HPB regimen. Moreover, to analyze the interplay between CD4+
and CD8+ T cells in mediating IFN-c production, in vitro blocking
with either anti CD4+ Ab, or anti CD8+ Ab, or both was
performed. In case of gp63 DNA vaccination, IFN-c response was
mainly mediated by CD8+ T cells, but CD4+ T cells also
contribute to this response. On the other hand, in case of rgp63
plus CpG vaccination, IFN-c was released mainly from CD4+ T
cells, and partially from CD8+ T cells.
The mechanism of protective action of CpG-ODN against VL
is correlated with the production of Th1 cytokine particularly, IL-
12. Moreover, CpG-ODN 1826 is known to activate Langerhans
cells, which in turn produce IL-12. Indeed endogenous IL-12 is
required for clearance of parasites, the level of IL-12 was studied in
all vaccinated mice. The levels was gradually increased in mice
receiving either gp63 DNA alone, or in association with CpG, or
in heterologously prime boost vaccination using CpG as adjuvant
before and after challenge infection in both STP and LTP studies.
Although, DNA-prime/Protein-boost showed significantly higher
IL-12 (p40) responses, which was enhanced after L. donovani
infection, lower IL-12 (p40) responses was obtained in mice
receiving rgp63 plus CpG before and after challenge infection.
Higher production of IFN-c, and IL-12 produced by HPB
regimen ultimately reflected towards highest nitrite production
from cultured splenocytes.
Intriguingly, expression of an established Th2 cytokine like IL-4
was down-regulated after challenge infection in groups of mice
receiving gp63 DNA mixed with CpG either homologously or
heterologously. Since HPB regimen showed higher IL-4 after
vaccination, and substantially lower IL-4 after challenge infection,
early mixed Th1/Th2 responses exhibited by this groups of mice
was therefore skewed in Th1 biased response after L. donovani
infection. In addition, since the fact that IL-10 has been shown to
block the Th1 activation and consequently a cytotoxic response by
down regulating IL-12 and IFN-c production, the disease
associated macrophage deactivating cytokine was down-regulated
significantly at twelve weeks post vaccination in mice vaccinated
with HPB regimen.
To understand the disease outcome underlying these results,
we therefore analyzed the parasite load in liver and spleen after
L. donovani challenge infection. Even in the susceptible BALB/c
mice, the gp63 DNA vaccination demonstrated potency and
durability against experimental VL. However, data obtained
through LDA suggest that DNA-prime/Protein-boost in
presence of CpG led to almost 107 fold and 1010 fold
reduction in hepatic and splenic parasite burden in LTP study.
This extent of protection, obtained in this study has till now
not been achieved in long-lasting protection through HPB
approach in susceptible BALB/c model against VL. DNA-
prime/Protein-boost vaccination showed durable protection,
which correlates with enhanced cellular and humoral responses
before and after L. donovani challenge. More surprisingly, the
course of L. major infection as measured by lesion development
in the footpad suggested that mice vaccinated with DNA-
prime/Protein-boost approach showed minor progress in lesion
size, which also validates the protective role of this vaccine
against murine CL.
Reasons for the enhanced efficacy of DNA vaccination over
protein plus adjuvant may include low levels of persistent Ag, or
presence of CpG motifs in their backbone [33]. Moreover, in this
study, the enhanced efficacy shown by HPB regimen over DNA
plus CpG is possibly due to the ability of the initial priming with
DNA to prime T cells to generate elevated secondary responses or
to produce high-affinity Ag-specific T cells whose numbers are
increased following boosting with protein Ag.
In summary, our study demonstrated that DNA-prime/Protein-
boost vaccination is effective in making durable vaccine against
Leishmania infection in susceptible BALB/c mice. To our
knowledge, this is the first detailed comparative study on
protective efficacy and durability of DNA/DNA, DNA-prime/
Protein-boost, Protein/Protein based vaccination against murine
VL.
Figure 7. Course of L. major infection in gp63 vaccinated BALB/c mice. Ten days, short-term protection (STP) study (A), and twelve weeks,
long-term protection (LTP) study (B), after last immunization, mice were challenged with 26106 L. major through s.c. route in the hind footpad. Lesion
development was monitored by measurement of footpad thickness for 10 weeks. Each point represents the average increase in footpad thickness 6
S.E of four individual mice per group. The experiment has been performed once. OV- only vector. **p,0.01, ***p,0.001 compared to controls (A).
*p,0.05 and **p,0.01 significantly differs from mice vaccinated with gp63 DNA, rgp63 plus CpG respectively (B).
doi:10.1371/journal.pone.0014644.g007
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